Curasight: Interview with Analyst Fredrik Thor

Research Interview



Redeye recently initiated coverage of Curasight, a Danish biotech company offering a theranostics platform (therapy + diagnostics) in PET imaging and radioligand (local radiation) therapy based on the novel use of the versatile uPAR cancer biomarker. Analyst Fredrik Thor talks us through the investment case.


Fredrik Thor

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.